NCT06593964

TACE With Thermosensitive Nanogel Versus Embosphere for HCC

Safety and Efficacy of TACE With Thermosensitive Nanogel Embolic Agent Versus Embosphere for Hepatocellular Carcinoma: A Prospective, Multicenter, Randomized Controlled, Non-inferiority Trial

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 188 (estimated)
• Sponsor: Zhongda Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.

Detailed description

This is a prospective, multicenter, randomized controlled, non-inferiority design trial. Participants who meet the criteria will be randomly assigned into the experimental group or the control group，with a ratio of 1:1. In the experimental group the Thermosensitive Nanogel Embolic Agent will be used in the TACE procedure, while in the control group the Embosphere microspheres will be used. The primary endpoint is disease control rate of the target lesions at 1 month after the last TACE treatment.

Conditions

• Unresectable Hepatocellular Carcinoma

Interventions

Type	Name	Description
DEVICE	Thermosensitive Nanogel Embolic Agent	Thermosensitive Nanogel Embolic Agent

Timeline

• Start date: 2024-09-10
• Primary completion: 2026-04-30
• Completion: 2026-04-30
• First posted: 2024-09-19
• Last updated: 2024-09-19

Locations

1 site across 1 country: China